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Sister chromatid exchange (SCE), which is considered 
a sensitive method in evaluation of mutagenicity and 
may be an indicator of carcinogenicity, was determined 
in lymphocytes from 8 patients with severe psoriasis 
who underwent treatment with oral methotrexate 
(MTX). During the treatment period (median 118 days, 
range 50-298 days) a significant increase in SCE com-
pared to the pretreatment value was found in 1 patient 
only. It is concluded that no long-term damage as meas-
ured by SCE occurs in lymphocytes from psoriasis pa-
tients treated with MTX. 
Sister chromatid exchange (SCE) is considered a sensitive 
method in evaluation of mutagenicity and may be an indicator 
of carcinoge nicity (1- 4]. Cytostatic chemicals, especially cross-
linking agents, have been shown to induce SCE [5,6]. In vitro 
experiments have shown that methotrexate (MTX) can pro-
duce enhanced SCE in proliferative cells [6] . 
In severe psoriasis MTX is often used as a potent treatment 
modality. Therefore in the present work we have examined t he 
frequency of SCE in lymphocytes from psoriasis patients before 
and during long-term treatment with MTX. 
MATERIALS AND METHODS 
Eight patien ts, 5 males and 3 fe males (median age 39.5 years, range 
29- 81 years) with severe psoriasis, who were submitted to treatment 
wi th methotrexate, participated in the study. The patients were treated 
with a single weekly oral dose of 25 mg MTX which was lowered later 
acco rdin g to its effect. There were 3 smokers and 5 nonsmokers. 
The first patient had SCE examined at 2, 4, 6, and 24 h after the 
initial MTX dose. In all patients SCE was determined before and at 
various intervals du ring the t reatment. Blood samples were taken about 
24 h after the MTX dose. The median duration of the MTX treatment 
was ll8 days (range 50-298 days). 
The SCE analyses were carried out by our standardized techn ique 
desc ribed elsewhere [7,8]. T hirty metaphases were scored for SCE in 
each specimen, one SCE being counted each time two adjacent seg-
ments of one of the chromatids in a chromosome were differently 
stained. The SCEs in the figures represent the mean count of the 30 
metaphases. 
When the SCEs were compared in the statistical calculations, each 
SCE was represented by 30 individual counts from the 30 metaphases. 
The t-test was used and differences were considered to be statistically 
significant when p < 0.05. 
RESULTS 
In Fig 1 SCE during 24 h after the initial MTX dose in the 
first patient is shown. No significant difference was found when 
compared to t he pretreatment va lue. 
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Abbrevi ations: 
MTX: methotrexate 
SCE: siste r chromatid exchange 
In Fig 2 SCE before and during treatment is shown. Smokers 
and nonsmokers were kept separate, as smokers have higher 
SCEs t han nonsmokers [9,10]. 
When the two most extreme values in patient 3 and t he most 
extreme SCE in patient 7 were excluded no significant differ-
ences between maximal and minimal SCE during treatment 
were found. 
In order to investigate whether SCE increased during long-
term treatment, pretreatment SCE for each patient was com-
pared to SCE obtained when t he patient had been treated for 
1 month or longer and was still on treatmen t. When the two 
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F IG 1. SCE (mean count of 30 metaphases) in the first patient 
during 24 h after an oral dose of 25 mg MTX. Vertical bars rep resent 
t he SEM. 
most extreme values in patient 3 were excluded, significant 
difference was found in patient 2 only, in whom SCE increased 
durin g treatment. 
DISCUSSION 
P rimarily we investigated whether an SCE-inducing effect of 
MTX could be recorded within t he first 24 h after oral intake 
and found no indication of such an immediate effect. Therefore 
t he trial was designed to clarify whether t here might be long-
term effects of MTX in doses by which psoriasis patients are 
treated. Within treatment periods ranging from 2-10 months 
signi ficant SCE increase was found in 1 patient only, whereas 
in 7 patients no increase was seen. We have no explanation 
why a single patient developed increased SCE; it is most likely 
to be considered as a type 1 error.* 
* A type 1 error rejects the tested hypothesis when it is true. (Re· 
mington RD, Schork MA: Statistics with Applications to the Biological 
and Health Sc iences. Englewood Cliffs, Prentice-Hall, p 195 
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FIG 2. SCE (mean count of 30 metaphases) in 3 smokers and 5 
nonsmokers during treatment with oral MTX in doses of 15-~5 mg 
week ly. Vertical bars represent t he SEM. * = value excluded m the 
statistical calculation . 
It h as been s hown t hat MTX induces SCE when incubated 
for a few hours with proliferating cell s (6] at a concentration 
(0.0 1 ,u.gjml) approximately 10-fold below maximal ser~m c_on-
centration after a n oral dose of 0.22 mg/kg [11] . These m vttro 
studies of SCE induct ion by MTX may have reflected DNA 
precursor p ool imba lance. ~t co~ld b~ spec~lated that cytosta~ic 
chemicals like MTX, whtch mterfere w1t h DNA synthes ts, 
would induce enha nced SCE only in t h ose parts of t he cell 
cycles during which t he chemical causes da mage to DN~. This 
could be t h e reason why Littlefield et a ! (12] have failed to 
demonstrate increased SCE in lymphocytes incubated in vitro 
with MTX at concentrations up to 2.5 J.Lg/ml. However long-
term treatment with MTX implies t hat a subgroup of the 
circulating lymphocytes has been exposed to the drug during 
the proliferative phase since, although som e lymph?cytes may 
have a li fe span of several mont hs, others have a rap1d turnover 
(13 ] . . . 
Our results indicate that during treatment of psonas1s pa-
tients with MTX, apparently no long-term damage as measured 
by SCE occurs in t he lymphocytes. In support of our results 
are t he findings by Bailin eta! [14 ] and Nyfors [15], who in 
epidemiologic studies found no increase in internal cancers 
a mong MTX-treated psoriatics. 
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